Tg Therapeutics (TGTX) Total Non-Current Liabilities (2010 - 2026)

Tg Therapeutics' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $944.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 126.47% year-over-year to $944.9 million; the TTM figure through Mar 2026 stood at $944.9 million (up 126.47% YoY), while the FY2025 annual figure was $413.1 million, up 17.52% from the prior year.
• Total Non-Current Liabilities was $944.9 million for Q1 2026 at Tg Therapeutics, up from $413.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $944.9 million in Q1 2026 to a low of $134.7 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $372.0 million across 5 years, with a median of $390.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities declined 5.19% in 2022, then soared 126.47% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $134.7 million in 2022, then increased by 25.22% to $168.7 million in 2023, then surged by 108.34% to $351.5 million in 2024, then grew by 17.52% to $413.1 million in 2025, then jumped by 128.72% to $944.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $944.9 million (Q1 2026), $413.1 million (Q4 2025), and $415.8 million (Q3 2025), per Business Quant data.